Electromed, Inc. (ELMD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended September 30, 2025 (First Quarter of Fiscal Year 2026). Electromed, Inc. develops, manufactures, and markets High Frequency Chest Wall Oscillation (HFCWO) airway clearance products, primarily the SmartVest System, for homecare and hospital markets in the U.S. and internationally. The company operates as a single reporting segment.
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Revenues | $16,887,000 | $14,668,000 |
| Gross Profit | $13,197,000 (78.1%) | $11,491,000 (78.3%) |
| Operating Income | $2,670,000 | $1,938,000 |
| Net Income | $2,136,000 | $1,474,000 |
| Diluted EPS | $0.25 | $0.16 |
| Cash from Operations | $169,000 | $2,309,000 |
| Cash and Equivalents | $14,113,000 | $13,864,000 |
| Working Capital | $35,800,000 | N/A |
| Debt (Line of Credit) | $0 Outstanding | $0 Outstanding |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 15.1% year-over-year. Growth was driven by a 12.7% increase in Homecare revenue (due to more sales reps and higher revenue per rep), a 51.7% surge in Hospital revenue (increased capital/disposal demand), and a 41.2% rise in Homecare distributor revenue.
- Profitability: Net income rose 44.9% to $2.136 million. Operating income increased 37.8% to $2.67 million, primarily due to revenue expansion.
- Expense Increases: SG&A expenses rose 9.6% to $10.286 million, driven by higher payroll (6.5% increase), travel (32.2% increase), and marketing (55.3% increase). R&D expenses increased 45.2% to $241,000 due to headcount and product enhancements.
- Cash Flow Volatility: Operating cash flow dropped significantly to $169,000 from $2.309 million in the prior year. This was primarily due to a $2.348 million decrease in accrued compensation (paying down prior liabilities) and a $515,000 increase in inventory.
- Share Repurchases: The company repurchased 40,848 shares for $1.003 million under a new $10 million authorization approved in September 2025.
Guidance, Outlook, and Risks
- Liquidity: Management believes working capital of ~$35.8 million and a $2.5 million available line of credit are sufficient for the next 12 months. The credit facility expires December 18, 2025, and requires renewal.
- Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted July 4, 2025, regarding the deductibility of R&D expenditures. This may affect future tax payments and deferred tax assets.
- Key Risks:
- Dependence on reimbursement from Medicare, Medicaid, and private payers.
- Supply chain constraints (component shortages, tariffs).
- Regulatory compliance and potential changes in healthcare regulations.
- Ability to renew the credit facility upon maturity.
- Management Commentary: The company continues to invest in sales force expansion and marketing to drive growth. No specific numerical guidance for the full fiscal year was provided in this filing.
Investor Verification Checklist
- Reimbursement Stability: Verify the stability of Medicare and private payer reimbursement rates for HFCWO devices, as this is a primary revenue driver.
- Working Capital Trends: Monitor the trend of accrued compensation and inventory levels to ensure operating cash flow stabilizes in future quarters.
- Debt Renewal: Confirm the renewal status of the $2.5 million credit facility before its December 2025 expiration.
- Tax Impact: Review future filings for the final determination of tax benefits related to the OBBBA and R&D expenditure amortization.
- Share Buyback Execution: Track the pace of the new $10 million share repurchase program and its impact on earnings per share.